[Topical tacrolimus in atopic dermatitis in children].
More than five years have passed since tacrolimus (Protopic) has been put on the market in Spain. This is sufficient time to reevaluate the successes and failures that this product has had after the great expectations created prior to the time when it was put on the market based on its extensive experimentation in clinical trials and very encouraging results. It is also time to reconsider the future of the indications and uses of tacrolimus, to reconsider our personal experiences with it and to offer answers to the new questions that have arisen after five years of using the product. Tacrolimus was sold for topical use in the treatment of atopic dermatitis. Since atopic dermatitis (AD) is a disease that affects children more frequently, tacrolimus is a product oriented directly toward use in children. This entails some added concerns. In this article, we review the most relevant findings that have arisen in the last five years in regards to the treatment of AD with tacrolimus in children.
Torrelo
A
A
Servicio de Dermatología, Hospital del Niño Jesús, Madrid, España. atorrelo@aedv.es
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000367:Age Factors; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008223:Lymphoma / Q000139:chemically induced; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000139:chemically induced; D013030:Spain; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus